DK200900369A - Solid dosage form of olmesartan medoxomil and amlodipine - Google Patents
Solid dosage form of olmesartan medoxomil and amlodipine Download PDFInfo
- Publication number
- DK200900369A DK200900369A DK200900369A DKPA200900369A DK200900369A DK 200900369 A DK200900369 A DK 200900369A DK 200900369 A DK200900369 A DK 200900369A DK PA200900369 A DKPA200900369 A DK PA200900369A DK 200900369 A DK200900369 A DK 200900369A
- Authority
- DK
- Denmark
- Prior art keywords
- dosage form
- solid dosage
- form according
- less
- concentration
- Prior art date
Links
- 239000007909 solid dosage form Substances 0.000 title claims 52
- 229940043092 olmesartan medoxomil and amlodipine Drugs 0.000 title claims 6
- 235000000346 sugar Nutrition 0.000 claims 9
- 150000008163 sugars Chemical class 0.000 claims 9
- 239000012535 impurity Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 7
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 4
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 4
- 229960000528 amlodipine Drugs 0.000 claims 4
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 4
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical group OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 1
- APZSGEHAFPIYQZ-UHFFFAOYSA-N 3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(COCCN)N=C(C)C(C(=O)OC)=C1C1=CC=CC=C1Cl APZSGEHAFPIYQZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960001199 olmesartan medoxomil Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84509006P | 2006-09-15 | 2006-09-15 | |
| US84509006 | 2006-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200900369A true DK200900369A (en) | 2009-03-16 |
Family
ID=38754721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200900369A DK200900369A (en) | 2006-09-15 | 2009-03-16 | Solid dosage form of olmesartan medoxomil and amlodipine |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20090175942A1 (fi) |
| JP (1) | JP5344620B2 (fi) |
| AT (1) | AT509493B1 (fi) |
| AU (1) | AU2007297333B2 (fi) |
| BR (1) | BRPI0716893A2 (fi) |
| CH (1) | CH703897B1 (fi) |
| DE (1) | DE212007000063U1 (fi) |
| DK (1) | DK200900369A (fi) |
| FI (1) | FI124122B (fi) |
| GB (1) | GB2454620B (fi) |
| IL (1) | IL197518A0 (fi) |
| IS (1) | IS8808A (fi) |
| MY (1) | MY157716A (fi) |
| NZ (1) | NZ575422A (fi) |
| PT (1) | PT2008032107W (fi) |
| RU (1) | RU2423975C2 (fi) |
| SE (1) | SE0900332L (fi) |
| SK (1) | SK288460B6 (fi) |
| TR (1) | TR200901984T1 (fi) |
| TW (1) | TWI399223B (fi) |
| WO (1) | WO2008032107A1 (fi) |
| ZA (1) | ZA200810616B (fi) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2598449Y2 (ja) | 1993-08-06 | 1999-08-09 | 株式会社ソミック石川 | ボールジョイント |
| WO2009113420A1 (ja) * | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | オルメサルタンメドキソミルを含む製剤の溶出性の改善 |
| TW201000097A (en) * | 2008-05-30 | 2010-01-01 | Daiichi Sankyo Co Ltd | Medicament for the prophylaxis or treament of hypertension |
| US20120115837A1 (en) * | 2009-04-30 | 2012-05-10 | Takeda Pharmaceutical Company Limited | Solid Preparation |
| MA34130B1 (fr) * | 2010-02-24 | 2013-04-03 | Sanofi Aventis Deutschland | Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation |
| EP2425859A1 (en) * | 2010-08-08 | 2012-03-07 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Olmesartan formulations |
| CN102028663B (zh) * | 2010-12-14 | 2011-11-30 | 北京万生药业有限责任公司 | 一种稳定的奥美沙坦酯固体制剂 |
| JP6018420B2 (ja) * | 2012-06-05 | 2016-11-02 | ニプロ株式会社 | アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物 |
| CN103565807B (zh) * | 2012-07-25 | 2015-11-04 | 天津市汉康医药生物技术有限公司 | 一种奥美沙坦酯氨氯地平药物组合物 |
| WO2014058047A1 (ja) * | 2012-10-12 | 2014-04-17 | 味の素株式会社 | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 |
| JP5871984B2 (ja) * | 2013-04-15 | 2016-03-01 | 株式会社三和化学研究所 | オルメサルタンメドキソミルを含有する医薬組成物 |
| WO2014188729A1 (ja) * | 2013-05-24 | 2014-11-27 | 持田製薬株式会社 | 経口用組成物 |
| EP2883539A1 (en) | 2013-12-12 | 2015-06-17 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of olmesartan and amlodipine |
| CN104739799B (zh) * | 2013-12-27 | 2018-01-05 | 辰欣药业股份有限公司 | 一种用于直接压片的苯磺酸氨氯地平组合物及其片剂制备方法 |
| KR102222917B1 (ko) * | 2014-06-25 | 2021-03-05 | 한림제약(주) | 암로디핀 및 올메사탄 메독소밀을 포함하는 약학 조성물 |
| CN104997778A (zh) * | 2015-07-08 | 2015-10-28 | 南京正大天晴制药有限公司 | 一种奥美沙坦酯氨氯地平药物组合物 |
| CN105902510A (zh) * | 2015-12-24 | 2016-08-31 | 嘉实（湖南）医药科技有限公司 | 一种奥美沙坦酯氨氯地平复方制剂的制备工艺 |
| MX2021010183A (es) * | 2019-02-26 | 2021-09-21 | Daewoong Pharmaceutical Co Ltd | Composicion farmaceutica con forma de dosificacion unica para tratar o prevenir la hipertension y la hiperlipidemia. |
| CN115300476B (zh) * | 2022-09-01 | 2024-04-16 | 华润双鹤药业股份有限公司 | 一种药物组合物及其制备方法 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3025292A (en) | 1962-03-13 | Reduction of i | ||
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US4772596A (en) * | 1986-10-09 | 1988-09-20 | Sankyo Company Limited | Dihydropyridine derivatives, their preparation and their use |
| US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| US5250521A (en) * | 1990-12-07 | 1993-10-05 | Merck & Co., Inc. | Substituted pyrazolopyrimidines as angiotensin II antagonists |
| US5260285A (en) * | 1990-12-07 | 1993-11-09 | Merck & Co., Inc. | Substituted imidazopyridazines as angiotensin II antagonists |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
| US5238942A (en) * | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
| US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| JPH05967A (ja) * | 1991-06-19 | 1993-01-08 | Yamanouchi Pharmaceut Co Ltd | 組織プラスミノーゲンアクチベーター含有製剤組成物 |
| US5246944A (en) * | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| FR2688781B1 (fr) * | 1992-03-23 | 1994-07-01 | Sanofi Elf | Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
| US5312820A (en) * | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| GB9405833D0 (en) * | 1994-03-24 | 1994-05-11 | Pfizer Ltd | Separation of the enantiomers of amlodipine |
| US5952006A (en) * | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
| US6251436B1 (en) * | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
| US5808084A (en) * | 1996-02-14 | 1998-09-15 | Pfizer, Inc. | Process for the preparation of 1,4-dihydropyridinedicarboxylic esters |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| US6420412B2 (en) * | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
| RU2220723C2 (ru) * | 1996-07-15 | 2004-01-10 | Санкио Компани, Лимитед | Средство и способ лечения или профилактики артериосклероза |
| WO1999000383A1 (en) * | 1997-06-27 | 1999-01-07 | Smithkline Beecham Corporation | Eprosartan monohydrate |
| US6630498B2 (en) * | 1997-08-06 | 2003-10-07 | Smithkline Beecham Corporation | Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation |
| US20010044584A1 (en) * | 1997-08-28 | 2001-11-22 | Kensey Kenneth R. | In vivo delivery methods and compositions |
| US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| US20030022928A1 (en) * | 1998-03-11 | 2003-01-30 | Smithkline Beecham Corporation | Novel compositions of eprosartan |
| US20020127254A1 (en) * | 1998-06-25 | 2002-09-12 | Lavipharm Laboratories Inc. | Devices for local and systemic delivery of active substance and methods of manufacturing thereof |
| US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
| JP2003521470A (ja) * | 1999-04-06 | 2003-07-15 | セプラコア インコーポレーテッド | ベンラファキシンの誘導体とその調製および使用方法 |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US6852743B1 (en) * | 1999-07-21 | 2005-02-08 | Takeda Pharmaceutical Company Limited | Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| MXPA02001694A (es) * | 1999-08-30 | 2002-08-06 | Aventis Pharma Gmbh | Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares. |
| US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| CZ301790B6 (cs) * | 2000-04-11 | 2010-06-23 | Sankyo Company Limited | Farmaceutický prípravek obsahující blokátor vápníku |
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
| EP1353727A2 (en) * | 2000-12-01 | 2003-10-22 | Novartis AG | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction |
| US20030138494A1 (en) * | 2001-05-15 | 2003-07-24 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US20040219208A1 (en) * | 2001-08-03 | 2004-11-04 | Ryu Kawamura | Sustained-release medicines |
| US6680334B2 (en) * | 2001-08-28 | 2004-01-20 | Pfizer Inc | Crystalline material |
| US7413751B2 (en) * | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| WO2004067003A1 (ja) * | 2003-01-31 | 2004-08-12 | Sankyo Company, Limited | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
| HUP0301537A3 (en) * | 2003-06-03 | 2005-07-28 | Egis Gyogyszergyar Nyilvanosan | Deramcyclane fumarate tablets and process for producing them |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| WO2005070462A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use |
| WO2006029057A1 (en) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Purification of olmesartan medoxomil |
| JP2006176496A (ja) * | 2004-11-24 | 2006-07-06 | Freunt Ind Co Ltd | 固形剤およびその製造方法 |
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| CA2592160A1 (en) * | 2005-01-03 | 2006-07-13 | Teva Pharmaceutical Industries Ltd. | Olmesartan medoxomil with reduced levels of impurities |
| JP2008538561A (ja) * | 2005-04-20 | 2008-10-30 | メルク エンド カムパニー インコーポレーテッド | アンジオテンシンｉｉ受容体アンタゴニスト |
| JP5063370B2 (ja) * | 2005-06-27 | 2012-10-31 | 第一三共株式会社 | 湿式造粒製薬の調製方法 |
| TWI405580B (zh) * | 2005-06-27 | 2013-08-21 | Sankyo Co | 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物 |
| KR20070009851A (ko) * | 2005-07-14 | 2007-01-19 | 씨제이 주식회사 | 클로피도그렐 황산수소염 함유 약학 조성물 |
| WO2007031933A2 (en) * | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| JP2009516707A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 固形製剤 |
| JP2007145646A (ja) * | 2005-11-28 | 2007-06-14 | Asahi Glass Co Ltd | プレス成型装置及びプレス成型装置の搬送品搬送方法 |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
-
2007
- 2007-09-14 TW TW096134347A patent/TWI399223B/zh active
- 2007-10-12 AU AU2007297333A patent/AU2007297333B2/en active Active
- 2007-10-12 CH CH00742/08A patent/CH703897B1/de unknown
- 2007-10-12 AT AT0939307A patent/AT509493B1/de active
- 2007-10-12 MY MYPI20091051A patent/MY157716A/en unknown
- 2007-10-12 NZ NZ575422A patent/NZ575422A/en unknown
- 2007-10-12 BR BRPI0716893-4A2A patent/BRPI0716893A2/pt not_active Application Discontinuation
- 2007-10-12 WO PCT/GB2007/003933 patent/WO2008032107A1/en not_active Ceased
- 2007-10-12 RU RU2009114166/15A patent/RU2423975C2/ru active
- 2007-10-12 DE DE212007000063U patent/DE212007000063U1/de not_active Ceased
- 2007-10-12 GB GB0903844A patent/GB2454620B/en active Active
- 2007-10-12 SE SE0900332A patent/SE0900332L/sv unknown
- 2007-10-12 PT PT2007003933A patent/PT2008032107W/pt unknown
- 2007-10-12 JP JP2009527899A patent/JP5344620B2/ja active Active
- 2007-10-12 TR TR2009/01984T patent/TR200901984T1/xx unknown
- 2007-10-12 SK SK5021-2009A patent/SK288460B6/sk unknown
-
2008
- 2008-12-15 ZA ZA200810616A patent/ZA200810616B/xx unknown
-
2009
- 2009-03-10 IL IL197518A patent/IL197518A0/en unknown
- 2009-03-11 US US12/401,748 patent/US20090175942A1/en not_active Abandoned
- 2009-03-12 IS IS8808A patent/IS8808A/is unknown
- 2009-03-13 FI FI20090094A patent/FI124122B/fi active IP Right Grant
- 2009-03-16 DK DK200900369A patent/DK200900369A/en not_active Application Discontinuation
-
2015
- 2015-06-09 US US14/734,893 patent/US20160129008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009114166A (ru) | 2010-10-20 |
| PT2008032107W (pt) | 2013-07-09 |
| SE0900332L (sv) | 2009-06-12 |
| ZA200810616B (en) | 2009-08-26 |
| MY157716A (en) | 2016-07-15 |
| IS8808A (is) | 2009-03-12 |
| RU2423975C2 (ru) | 2011-07-20 |
| FI20090094L (fi) | 2009-03-13 |
| JP2011500505A (ja) | 2011-01-06 |
| AU2007297333A1 (en) | 2008-03-20 |
| NZ575422A (en) | 2011-01-28 |
| TR200901984T1 (tr) | 2009-08-21 |
| GB2454620A (en) | 2009-05-13 |
| CH703897B1 (de) | 2012-04-13 |
| AT509493A5 (de) | 2011-09-15 |
| TWI399223B (zh) | 2013-06-21 |
| AU2007297333B2 (en) | 2010-10-28 |
| US20160129008A1 (en) | 2016-05-12 |
| WO2008032107A1 (en) | 2008-03-20 |
| IL197518A0 (en) | 2009-12-24 |
| TW200817052A (en) | 2008-04-16 |
| BRPI0716893A2 (pt) | 2014-05-06 |
| GB2454620B (en) | 2011-08-17 |
| GB0903844D0 (en) | 2009-04-22 |
| SK288460B6 (sk) | 2017-03-01 |
| FI124122B (fi) | 2014-03-31 |
| AT509493B1 (de) | 2012-01-15 |
| DE212007000063U1 (de) | 2009-05-14 |
| US20090175942A1 (en) | 2009-07-09 |
| HK1127282A1 (en) | 2009-09-25 |
| JP5344620B2 (ja) | 2013-11-20 |
| SK50212009A3 (sk) | 2009-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200900369A (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
| CA2846387C (en) | Methods for treating cardiovascular disorders | |
| CA2483199A1 (en) | High drug load tablet of imatinib | |
| JP2010132654A5 (fi) | ||
| CA2524091A1 (en) | Pharmaceutical formulation of the telmisartan sodium salt | |
| US8785432B2 (en) | Pharmaceutical compositions of amlodipine and valsartan | |
| WO2010009618A1 (zh) | 用于治疗高血压和代谢综合症的药物组合物及其应用 | |
| JP6231959B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤 | |
| WO2017054787A1 (en) | Pharmaceutical composition comprising the combination of candesartan, amlodipine and hydrochlorothiazide | |
| EP2883539A1 (en) | Pharmaceutical combinations of olmesartan and amlodipine | |
| WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist | |
| RU2008136315A (ru) | Композиции ситаксентана натрия | |
| Croom et al. | Irbesartan: a review of its use in hypertension and diabetic nephropathy | |
| WO2018062685A1 (ko) | 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제 | |
| Plosker et al. | Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension | |
| Neldam et al. | Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures | |
| CN101632672B (zh) | 一种用于治疗高血压的复方药物组合物 | |
| JP5241511B2 (ja) | 溶出性の改善された医薬組成物 | |
| US20150094318A1 (en) | Methods of colchicine administration | |
| US20190175551A1 (en) | Medicine for treating renal disease | |
| US8022086B2 (en) | Therapeutic agent for glomerular disease | |
| KR20150034120A (ko) | 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제 | |
| EP2407159B1 (en) | Pharmaceutical compositions of olmesartan | |
| SG185474A1 (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| CA2562142A1 (en) | Prolonged-release compositions comprising torasemide and a matrix-forming polymer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PHB | Application deemed withdrawn due to non-payment or other reasons |
Effective date: 20160725 |